Progress in clinical control of myopia with low concentration of atropine
低浓度阿托品控制近视的临床研究进展

摘要

近视问题已经成为一个全球性的公共卫生挑战，它影响着世界各个角落的人们的生活质量。根据最近的统计数据，我们不难发现，全球近视以及高度近视的发病率正在不断攀升。这种不断上升的趋势不仅给社会经济带来了巨大的压力和负担，而且高度近视还可能增加患者患上不可逆性致盲眼病的风险，从而严重影响到患者的生活质量[1]。鉴于这种情况，寻找有效的方法来减缓甚至停止近视的发生和进展显得尤为紧迫和关键。目前，矫正近视的方法多种多样，包括使用毒蕈碱拮抗剂、角膜塑形镜、多焦眼镜以及传统的框架眼镜等[2]。在这些方法中，低浓度阿托品作为毒蕈碱拮抗剂的一种，在控制儿童和青少年近视进展方面显示出了显著的效果。本文旨在对低浓度阿托品在延缓近视进展方面的临床研究进行系统的总结，并对其未来应用的可能性进行展望，希望能够为近视的防治提供新的思路和方法。

Abstract

The problem of myopia has become a global public health challenge that affects the quality of life of people in all corners of the world. According to recent statistics, it is not difficult to find that the global incidence of myopia and high myopia is increasing. This increasing trend not only brings great pressure and burden to the social economy, but also high myopia may increase the risk of irreversible blindness eye disease, which will seriously affect the quality of life [1]. In view of this situation, it is particularly urgent and critical to find effective ways to slow down and even stop the occurrence and progression of myopia. Currently, there are various methods to correct myopia, including the use of [2] such as muscarinic antagonists, orthokeratology lenses, multifocal glasses, and traditional frame glasses. Among these methods, low concentrations of atropine, as one of the muscarinic antagonists, have shown remarkable effects in controlling myopia progression in children and adolescents. This paper aims to make a systematic summary of the clinical research of low-concentration atropine in delaying the progression of myopia, and to prospect the possibility of its future application, hoping to provide new ideas and methods for the prevention and treatment of myopia.